Delivery Order SPE2DB24D9222-SPE2DB25FAZGM

Award Date 4/18/25
Potential Completion Date 4/21/25
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $4,169.59 order is for the supply of 120 units of the prescription medication Xtandi 40 mg tablet. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA, which enables the agency to issue delivery orders for a range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $77,604.30, is for the delivery of 120 capsules of the prescription drug Xtandi 40 mg. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at $499,999,999 and valid through...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,339.18, is for the delivery of 120 tablets of the prescription drug Xtandi 40 mg. This delivery order is issued under a larger single-award Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at $499,999,999 and valid...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,169.59 firm fixed-price contract is for the delivery of 120 units of the prescription drug Xtandi 40 mg tablets. The order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA, which enables the agency to issue delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,169.59 contract is for the delivery of 120 units of the prescription drug Xtandi 40 mg tablets. It is not associated with a set-aside program. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Xtandi 80 mg tablets. This delivery order is part of a larger single-award indefinite delivery contract (IDC) between the DLA and DMS Pharmaceutical Group, valued up to $499,999,999, that runs through December 31, 2025. The IDC...
This is a firm-fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 contract is for the delivery of 120 capsules of the prescription drug Xtandi 40 mg by April 22, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $8,339.18, is for the delivery of Xtandi 80 mg tablets. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which runs through December 31, 2025. The IDC allows the DLA to issue firm...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,169.59 contract is for the delivery of Xtandi 80 mg tablets. This order is part of a larger $499,999,999 indefinite delivery contract (IDC) with DMS Pharmaceutical Group to provide a comprehensive range of pharmaceutical items, including branded and generic prescription drugs,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $12,508.77 contract is for the delivery of 120 tablets of the prescription drug Xtandi 40 mg. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to issue firm fixed-price delivery orders for...
  • SPE2DB24D9222
    Indefinite Delivery Contract
  • SPE2DB24D9222-SPE2DB25FAZGM
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,017.54 contract is for the delivery of Xtandi 40 mg tablets. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, which allows the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The contract has no set-aside designation and is valid through April 2025.

Generated 7/18/25, 9:45 AM